Literature DB >> 27096755

Longitudinal Changes in Tear Evaporation Rates After Eyelid Warming Therapies in Meibomian Gland Dysfunction.

Sharon Yeo1, Jen Hong Tan2, U Rajendra Acharya2, Vidya K Sudarshan2, Louis Tong3.   

Abstract

PURPOSE: Lid warming is the major treatment for meibomian gland dysfunction (MGD). The purpose of the study was to determine the longitudinal changes of tear evaporation after lid warming in patients with MGD.
METHODS: Ninety patients with MGD were enrolled from a dry eye clinic at Singapore National Eye Center in an interventional trial. Participants were treated with hot towel (n = 22), EyeGiene (n = 22), or Blephasteam (n = 22) twice daily or a single 12-minute session of Lipiflow (n = 24). Ocular surface infrared thermography was performed at baseline and 4 and 12 weeks after the treatment, and image features were extracted from the captured images.
RESULTS: The baseline of conjunctival tear evaporation (TE) rate (n = 90) was 66.1 ± 21.1 W/min. The rates were not significantly different between sexes, ages, symptom severities, tear breakup times, Schirmer test, corneal fluorescein staining, or treatment groups. Using a general linear model (repeat measures), the conjunctival TE rate was reduced with time after treatment. A higher baseline evaporation rate (≥ 66 W/min) was associated with greater reduction of evaporation rate after treatment. Seven of 10 thermography features at baseline were predictive of reduction in irritative symptoms after treatment.
CONCLUSIONS: Conjunctival TE rates can be effectively reduced by lid warming treatment in some MGD patients. Individual baseline thermography image features can be predictive of the response to lid warming therapy. For patients that do not have excessive TE, additional therapy, for example, anti-inflammatory therapy, may be required.

Entities:  

Mesh:

Year:  2016        PMID: 27096755     DOI: 10.1167/iovs.16-19088

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

Review 1.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

2.  Evaluation of Monocular Treatment for Meibomian Gland Dysfunction with an Automated Thermodynamic System in Elderly Chinese Patients: A Contralateral Eye Study.

Authors:  Yinying Zhao; Jialu Xie; Junhua Li; Yana Fu; Xiaolei Lin; Shangrong Wang; Jiling Ma; Yune Zhao
Journal:  J Ophthalmol       Date:  2016-12-27       Impact factor: 1.909

3.  Acupuncture and herbal formulation compared with artificial tears alone: evaluation of dry eye symptoms and associated tests in randomised clinical trial.

Authors:  Louis Tong; Hla Myint Htoon; Aihua Hou; Rajendra Udyavara Acharya; Jen-Hong Tan; Qi-Ping Wei; Pat Lim
Journal:  BMJ Open Ophthalmol       Date:  2018-06-18

4.  Effect of warming eyelids on tear film stability and quality of life in visual display terminal users: a randomized controlled trial.

Authors:  Chi-Chin Sun; Chia-Yi Lee; Yih-Shiou Hwang; Igaki Michihito; Kyoko Tagami; Ching-Hsi Hsiao
Journal:  Sci Rep       Date:  2020-10-09       Impact factor: 4.379

5.  TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial.

Authors:  Jonatan Olafsson; Xiaoran Lai; Erlend Christoffer Sommer Landsend; Snorri Olafsson; Eric Parissi; Øygunn A Utheim; Sten Raeder; Reza A Badian; Neil Lagali; Darlene A Dartt; Tor P Utheim
Journal:  Sci Rep       Date:  2021-11-17       Impact factor: 4.379

6.  Effect of a single vectored thermal pulsation treatment of Meibomian gland dysfunction patients under controlled environmental conditions.

Authors:  Andrea Novo-Diez; Alberto López-Miguel; Itziar Fernández; Marta Blanco-Vázquez; Cristina Valencia-Sandonís; Amalia Enríquez-de-Salamanca; María J González-García; Margarita Calonge
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

Review 7.  Non-pharmaceutical treatment options for meibomian gland dysfunction.

Authors:  Reiko Arita; Shima Fukuoka
Journal:  Clin Exp Optom       Date:  2020-01-13       Impact factor: 2.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.